Goldman Sachs Group Inc Aquestive Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 524,685 shares of AQST stock, worth $3.19 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
524,685
Previous 818,849
35.92%
Holding current value
$3.19 Million
Previous $2.37 Million
26.87%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding AQST
# of Institutions
132Shares Held
49.3MCall Options Held
64.2KPut Options Held
204K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$59.7 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$33.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.33MShares$26.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.98MShares$18.1 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.19MShares$13.3 Million0.32% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $324M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...